Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cellgram for alcoholic liver cirrhosis
NCT03838250Phase 1Unknown
- Sponsor
- Pharmicell Co., Ltd.
- Start
- Jun 2019
- Primary completion
- Mar 2021
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Cellgram-LC in alcoholic liver cirrhosis, sponsored by Pharmicell Co., Ltd. Primary endpoint: Incidence of Serious Adverse Events at 12 months. Status: unknown.
02
Drugs
Cellgram-LC
03
Conditions
alcoholic liver cirrhosis
Beyond the preview
Go deeper on NCT03838250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03838250.